STOCK TITAN
  1. Home
  2. News
  3. SAVA

Cassava Sciences, Inc. - SAVA STOCK NEWS

Welcome to our dedicated page for Cassava Sciences news (Ticker: SAVA), a resource for investors and traders seeking the latest updates and insights on Cassava Sciences stock.

Cassava Sciences, Inc. (NASDAQ: SAVA) is a clinical-stage biotechnology company dedicated to the development of innovative solutions for the treatment and detection of Alzheimer's disease. The company's primary focus is on two groundbreaking product candidates: simufilam and SavaDx.

Simufilam is an oral therapeutic designed to treat Alzheimer's disease. It is currently undergoing two randomized, placebo-controlled Phase 3 clinical trials to assess its efficacy in patients with Alzheimer's dementia. This novel treatment aims to improve cognitive function and slow down the progression of the disease.

SavaDx, the company's investigational diagnostic product, represents a significant advancement in the early detection of Alzheimer's disease. This innovative diagnostic tool can potentially identify the presence of Alzheimer's years before symptoms become apparent, using a small sample of blood.

In addition to its clinical trials, Cassava Sciences recently announced a major financial achievement. The company secured over $125 million from the exercise of warrants, reflecting strong investor confidence. These funds will support the ongoing development and potential commercialization of their innovative products.

Cassava Sciences' mission is to address the urgent unmet medical needs of Alzheimer's patients and their families through rigorous scientific research and development. With its dedicated team and promising product pipeline, the company is well-positioned to make a significant impact on the landscape of Alzheimer's treatment and diagnosis.

For the latest updates on Cassava Sciences’ projects, partnerships, and financial performance, investors can refer to the company's filings with the Securities and Exchange Commission (SEC). For more detailed information, contact Eric Schoen, Chief Financial Officer, at (512) 501-2450 or ESchoen@CassavaSciences.com.

News

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

Rhea-AI Summary
Cassava Sciences, Inc. announces positive interim safety review of simufilam in Phase 3 trials for Alzheimer's disease treatment. DSMB recommends trials continue as planned. Final clinical safety data expected at program conclusion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
clinical trial
-
News

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

Rhea-AI Summary
Cassava Sciences to Present Oral Simufilam Data at AD/PD 2024 Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
-
News

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Rhea-AI Summary
Cassava Sciences, Inc. reported $121.1 million in cash and cash equivalents at December 31, 2023, with an additional $21.8 million raised in 2024. The company's Phase 3 studies have over 555 participants, with topline data readout expected year-end 2024. An internal investigation found no evidence of research misconduct. Net loss for 2023 was $97.2 million, with increased R&D and G&A expenses. Corporate highlights include dividend distribution, positive safety findings, new Board members, and biological activity confirmation of simufilam.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
earnings
News

CASSAVA SCIENCES SHAREHOLDER ACTION REMINDER

Rhea-AI Summary
Faruqi & Faruqi, LLP is investigating potential claims against Cassava Sciences, Inc. for violating federal securities laws by allegedly making false statements regarding its drug research programs. The complaint alleges data manipulation in support of simufilam, leading to significant financial and reputational harm. Cassava's stock price fell 15.28% following reports of possible scientific misconduct by a researcher associated with the program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
-
News

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

Rhea-AI Summary
Cassava Sciences, Inc. reported top-line results of a two-year clinical safety study of simufilam, an investigational oral drug for the treatment of Alzheimer’s disease dementia. Patients with mild Alzheimer’s who received simufilam treatment continuously for two years had no decline in ADAS-Cog scores, while those who received non-continuous treatment declined by 1 point. Patients with moderate Alzheimer’s who received simufilam treatment continuously for two years declined 11.05 points on ADAS-Cog. The drug was safe and well-tolerated, with no drug-related serious adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
none
-
News

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

Rhea-AI Summary
Cassava Sciences, Inc. (Nasdaq: SAVA) announced the completion of a distribution of warrants to its shareholders. The Warrants now trade on Nasdaq under the ticker SAVAW. Stockholders received four (4) Warrants for each ten (10) shares of the Company’s common stock held as of December 22, 2023 (the 'Record Date'). Each Warrant entitles the holder to purchase one share of Cassava Sciences’ common stock at an initial exercise price of $33.00 per share, with the option of receiving an additional 0.5 of a share per Warrant through the Bonus Share Program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
dividends
News

Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders

Rhea-AI Summary
Cassava Sciences, Inc. (Nasdaq: SAVA) announces pro rata dividend distribution of warrants to shareholders of record. Shareholders will receive 4 warrants for every 10 shares held as of December 22, 2023. Warrants are expected to list and trade on Nasdaq. Warrant holders who choose to exercise during an early period will also receive an additional 0.5 of a common share per warrant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.96%
Tags
dividends
-
News

Cassava Sciences Appoints Three New Members to its Board of Directors

Rhea-AI Summary
Cassava Sciences, Inc. (Nasdaq: SAVA) appoints three new board members with extensive experience in drug development, healthcare M&A, and cybersecurity. Dr. Nicaise has 14 new drug approvals, Mr. Gravier is a CFO of a biotech company, and Mr. Anderson has operational experience in cybersecurity and counterintelligence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.37%
Tags
management
-
News

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

Rhea-AI Summary
Cassava Sciences, Inc. completed enrollment for Phase 3 trials evaluating oral simufilam in Alzheimer's, with over 1,900 patients randomized. Top-line results for the 52-week Phase 3 trial expected approximately year-end 2024, and for the 76-week Phase 3 trial expected approximately mid-year 2025. MRI safety data suggests simufilam is not associated with ARIA. The company reported $142.4 million in cash and cash equivalents at September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
earnings
News

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

Rhea-AI Summary
Cassava Sciences completes patient enrollment in Phase 3 trials for oral simufilam in Alzheimer's disease dementia. Top-line results for 52-week trial expected by year-end 2024, and 76-week trial expected by mid-year 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
clinical trial

FAQ

What is the current stock price of Cassava Sciences (SAVA)?

The current stock price of Cassava Sciences (SAVA) is $2.715 as of January 15, 2025.

What is the market cap of Cassava Sciences (SAVA)?

The market cap of Cassava Sciences (SAVA) is approximately 131.4M.

What is Cassava Sciences, Inc.?

Cassava Sciences is a clinical-stage biotechnology company focused on developing treatments and diagnostics for Alzheimer's disease.

What are the main products of Cassava Sciences?

Their main products are simufilam, a treatment for Alzheimer's, and SavaDx, a diagnostic tool for early detection of the disease.

What is simufilam?

Simufilam is an oral therapeutic for Alzheimer's disease, currently in Phase 3 clinical trials to assess its efficacy in improving cognitive function.

What is SavaDx?

SavaDx is an investigational diagnostic product that can detect Alzheimer's disease from a small blood sample, potentially years before symptoms appear.

What recent financial achievements has Cassava Sciences made?

Cassava Sciences recently secured over $125 million from the exercise of warrants, reflecting strong investor confidence.

How can I get more information about Cassava Sciences?

For more information, you can contact Eric Schoen, Chief Financial Officer, at (512) 501-2450 or via email at ESchoen@CassavaSciences.com.

Where can I find the latest updates about Cassava Sciences?

Latest updates can be found in the company's filings with the Securities and Exchange Commission (SEC) and through official press releases.

What is the current status of simufilam's clinical trials?

Simufilam is currently in Phase 3 clinical trials to determine its effectiveness in treating Alzheimer's disease dementia.

What makes SavaDx an innovative diagnostic tool?

SavaDx can potentially detect Alzheimer's disease from a small blood sample years before clinical symptoms appear.

What is Cassava Sciences' mission?

Cassava Sciences aims to address the unmet medical needs of Alzheimer's patients through rigorous scientific research and development.
Stock SAVA logo
Cassava Sciences, Inc.

Nasdaq:SAVA

SAVA Rankings

#4221 Ranked by Market Cap
N/A Ranked by Dividends

SAVA Stock Data

131.39M
42.04M
12.65%
29.93%
36.62%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
AUSTIN